Table 1 Patient demographic and dabigatran dosing characteristics

Mean Age ± SD (years)

81.3 ± 4.5

Female (%)

44.5

Mean time after last dabigatran dose ± SD (hours)

13.1 ± 2.3

Mean weight ± SD (kg)

83.0 ± 21.1

Body mass index ± SD (kg/m²)

28.9 ± 4.7

Baseline Renal Clearance ± SD (mL/min)

 Cockcroft-Gault

68.4 ± 28.4

 CKD-EPI

40.9 ± 12.3

Dabigatran dosage, n (%)

 75 mg twice daily

4 (44.4)

 150 mg twice daily

5 (55.6)

Cormorbidities (n, %)

 Chronic obstructive pulmonary disease

3 (33.3)

 Diabetes Mellitus

4 (44.4)

 Heart Failure

3 (33.3)

 Malignancy

2 (22.2)

 Thyroid Disease

4 (44.4)

 Coronary Artery Disease

2 (22.2)

Mean HPLC-MS/MS dabigatran level ± SD (ng/mL)^a

161.1 ± 104.1

Mean chromogenic anti-IIa dabigatran level ± SD (ng/mL)^a

161.9 ± 104.8